Spandidos Publications Logo
  • About
    • About Spandidos
    • Aims and Scopes
    • Abstracting and Indexing
    • Editorial Policies
    • Reprints and Permissions
    • Job Opportunities
    • Terms and Conditions
    • Contact
  • Journals
    • All Journals
    • Oncology Letters
      • Oncology Letters
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Oncology
      • International Journal of Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular and Clinical Oncology
      • Molecular and Clinical Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Experimental and Therapeutic Medicine
      • Experimental and Therapeutic Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Molecular Medicine
      • International Journal of Molecular Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Biomedical Reports
      • Biomedical Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Reports
      • Oncology Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular Medicine Reports
      • Molecular Medicine Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • World Academy of Sciences Journal
      • World Academy of Sciences Journal
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Functional Nutrition
      • International Journal of Functional Nutrition
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Epigenetics
      • International Journal of Epigenetics
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Medicine International
      • Medicine International
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
  • Articles
  • Information
    • Information for Authors
    • Information for Reviewers
    • Information for Librarians
    • Information for Advertisers
    • Conferences
  • Language Editing
Spandidos Publications Logo
  • About
    • About Spandidos
    • Aims and Scopes
    • Abstracting and Indexing
    • Editorial Policies
    • Reprints and Permissions
    • Job Opportunities
    • Terms and Conditions
    • Contact
  • Journals
    • All Journals
    • Biomedical Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Experimental and Therapeutic Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Epigenetics
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Functional Nutrition
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Molecular Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Medicine International
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular and Clinical Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular Medicine Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Letters
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • World Academy of Sciences Journal
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
  • Articles
  • Information
    • For Authors
    • For Reviewers
    • For Librarians
    • For Advertisers
    • Conferences
  • Language Editing
Login Register Submit
  • This site uses cookies
  • You can change your cookie settings at any time by following the instructions in our Cookie Policy. To find out more, you may read our Privacy Policy.

    I agree
Search articles by DOI, keyword, author or affiliation
Search
Advanced Search
presentation
Molecular Medicine Reports
Join Editorial Board Propose a Special Issue
Print ISSN: 1791-2997 Online ISSN: 1791-3004
Journal Cover
September-2024 Volume 30 Issue 3

Full Size Image

Sign up for eToc alerts
Recommend to Library

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

Medicine International

An International Open Access Journal Devoted to General Medicine.

Journal Cover
September-2024 Volume 30 Issue 3

Full Size Image

Sign up for eToc alerts
Recommend to Library

  • Article
  • Citations
    • Cite This Article
    • Download Citation
    • Create Citation Alert
    • Remove Citation Alert
    • Cited By
  • Similar Articles
    • Related Articles (in Spandidos Publications)
    • Similar Articles (Google Scholar)
    • Similar Articles (PubMed)
  • Download PDF
  • Download XML
  • View XML
Article

Expression of ISG60 is induced by TLR3 signaling in BEAS‑2B bronchial epithelial cells: Possible involvement in CXCL10 expression

  • Authors:
    • Yusuke Tanaka
    • Tadaatsu Imaizumi
    • Yuri Kobori
    • Mayuki Tachizaki
    • Toshihiro Shiratori
    • Masaki Dobashi
    • Mami Sato
    • Shogo Kawaguchi
    • Kazuhiko Seya
    • Sadatomo Tasaka
  • View Affiliations / Copyright

    Affiliations: Department of Respiratory Medicine, Hirosaki University Graduate School of Medicine, Hirosaki, Aomori 036‑8562, Japan, Department of Vascular and Inflammatory Medicine, Hirosaki University Graduate School of Medicine, Hirosaki, Aomori 036‑8562, Japan, Department of Otorhinolaryngology Head and Neck Surgery, Hirosaki University Graduate School of Medicine, Hirosaki, Aomori 036‑8562, Japan
  • Article Number: 151
    |
    Published online on: July 1, 2024
       https://doi.org/10.3892/mmr.2024.13276
  • Expand metrics +
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
Cited By (CrossRef): 0 citations Loading Articles...

This article is mentioned in:



Abstract

Viral infections in the respiratory tract are common, and, in recent years, severe acute respiratory syndrome coronavirus 2 outbreaks have highlighted the effect of viral infections on antiviral innate immune and inflammatory reactions. Specific treatments for numerous viral respiratory infections have not yet been established and they are mainly treated symptomatically. Therefore, understanding the details of the innate immune system underlying the airway epithelium is crucial for the development of new therapies. The present study aimed to investigate the function and expression of interferon (IFN)‑stimulated gene (ISG)60 in non‑cancerous bronchial epithelial BEAS‑2B cells exposed to a Toll‑like receptor 3 agonist. BEAS‑2B cells were treated with a synthetic TLR3 ligand, polyinosinic‑polycytidylic acid (poly IC). The mRNA and protein expression levels of ISG60 were analyzed using reverse transcription‑quantitative PCR and western blotting, respectively. The levels of C‑X‑C motif chemokine ligand 10 (CXCL10) were examined using an enzyme‑linked immunosorbent assay, and the effects of knockdown of IFN‑β, ISG60 and ISG56 were examined using specific small interfering RNAs. Notably, ISG60 expression was increased in proportion to poly IC concentration, and recombinant human IFN‑β also induced ISG60 expression. By contrast, knockdown of IFN‑β and ISG56 decreased ISG60 expression, and ISG60 knockdown reduced CXCL10 and ISG56 expression. These findings suggested that ISG60 is partly implicated in CXCL10 expression and that ISG60 may serve a role in the innate immune response of bronchial epithelial cells. The present study highlights ISG60 as a potential target for new therapeutic strategies against viral infections in the airway.

Introduction

Respiratory infections caused by various viruses, such as influenza, respiratory syncytial virus, parainfluenza, rhinovirus and human coronavirus (including severe acute respiratory syndrome coronavirus 2), pose significant public health challenges (1). Currently, specific antiviral treatments for a number of these viruses are lacking, often leaving symptomatic therapy as the primary approach for managing viral respiratory infections. Furthermore, the ongoing threat of potential pandemics underscores the need to explore novel approaches to combat pulmonary viral infections. Because epithelial cells in the respiratory tract are vulnerable to various viral pathogens, a detailed understanding of the immune system in the airway epithelium is essential for developing new therapeutic strategies.

The innate immune system is a frontline defense against invading microbes, orchestrating subsequent adaptive immune responses (2). Recognition of pathogen-associated molecular patterns by pattern-recognition receptors triggers the initiation of innate immune responses. Among these receptors, Toll-like receptor 3 (TLR3) serves as a key receptor for virus-derived double-stranded RNA (dsRNA) (3), and is prominently expressed in airway epithelial cells. Activation of TLR3 by dsRNA leads to the activation of NF-κB and interferon regulatory factor 3, resulting in the production of cytokines and chemokines that are pivotal in orchestrating immune and inflammatory responses (4–6). Central to this antiviral defense mechanism is the induction of type I interferons (IFNs) by TLR3 signaling, with IFN-β emerging as a principal type I IFN in bronchial epithelial cells (7). Following IFN-β production, hundreds of IFN-stimulated genes (ISGs) are upregulated, forming a complex network that modulates both innate and adaptive immune responses (8). For example, IFN-β induces the expression of C-X-C motif chemokine ligand 10 (CXCL10), a chemokine that promotes lymphocyte chemotaxis (9), and melanoma differentiation-associated gene 5 (MDA5), a dsRNA receptor and signaling molecule (10). Furthermore, ISG56 and ISG60 have also been speculated to contribute to antiviral immunity alongside other ISGs (11).

Despite extensive studies (12,13) on the molecular mechanisms underlying inflammatory responses and innate antiviral immunity in airway epithelial cells, the specific roles of ISGs remain incompletely understood. ISG56, also known as IFN-induced protein with tetratricopeptide repeats 1 (IFIT1), encodes a protein with a helix-turn-helix four-repeat motif that mediates various antiviral responses (11). A previous study has shown that ISG56 mediates CXCL10 expression in BEAS-2B bronchial epithelial cells during TLR3 signaling (14). ISG60 is another IFIT protein, also known as retinoic acid-inducible gene G (15) and IFIT3 (16), which induces IFN-β signaling and suppresses adenovirus early gene expression in alveolar adenocarcinoma cell-derived 293FT cells, A549 cells and immortalized normal human diploid fibroblasts (17). These studies suggest that ISG60 may have a crucial role in host defense against adenovirus infection; however, the mechanisms by which ISG60 exerts its antiviral function via TLR3 signaling in airway epithelial cells remain unknown. The present study aimed to investigate the function and expression of ISG60 in BEAS-2B cells primed with a TLR3 ligand, polyinosinic-polycytidylic acid (poly IC).

Materials and methods

Cell culture

Noncancerous bronchial epithelial cell-derived BEAS-2B cells (American Type Culture Collection) were cultured at 37°C and 5% CO2 in Dulbecco's modified Eagle's medium (Thermo Fisher Scientific, Inc.) supplemented with 10% fetal bovine serum (Biowest), 100 U/ml penicillin, 100 µg/ml streptomycin B and 250 ng/ml Amphotericin B (Nacalai Tesque, Inc.) as previously described (14). Poly IC (cat. no. P9582; MilliporeSigma) was added to the cell culture medium for treatment at 37°C. To examine the concentration-dependent effect of poly IC, the cells were treated with 3, 5, 10, 30 and 50 µg/ml poly IC for 16 h (for mRNA expression analysis) or 24 h (for protein expression analysis). In time course experiments, the cells were treated with 30 µg/ml poly IC for 2, 4, 8, 16 and 24 h. For RNA interference, cells at 50–70% density cultured for 24 h in antibiotic-free medium were transfected at 37°C with either negative control small interfering RNA (siRNA) (cat. no. 1027281; Qiagen GmbH), or siRNAs against IFN-β (custom synthesized by Invitrogen; Thermo Fisher Scientific, Inc.) (18), ISG56 (cat. no. SI02660777; Qiagen GmbH) or ISG60 (cat. no. SI04197788 as ISG60 si-1; cat. no. SI03152737 as ISG60 si-2; Qiagen GmbH) at a concentration of 10 pmol/ml using Lipofectamine® RNAiMAX (Invitrogen; Thermo Fisher Scientific, Inc.). After 4 h of transfection, the medium was changed, and the cells were subjected to subsequent experiments 48 h after transfection. The siRNA sequences for IFN-β, ISG56 and ISG60 were as follows. IFN-β siRNA, sense 5′-CCAUGAGCUACAACUUGCUUGGAUU-3′, antisense 5′-AAUCCAAGCAAGUUGUAGUCUAUGG-3′; ISG56 siRNA, sense 5′-GGAUCAGAUUGAAUUCCUATT-3′, antisense 5′-UAGGAAUUCAAUCUGAUCCAA-3′; ISG60 siRNA-1, sense 5′-AGAUGAUUGAAGCACUAAATT-3′, antisense UUUAGUGCUUCAAUCAUCUCT-3′; ISG60 siRNA-2, sense 5′-GUCAUGGACUAUUCGAAUATT-3′ and antisense 5′-UAUUCGAAUAGUCCAUAGCAT-3′. The cells were also treated with recombinant human [r(h)]IFN-β (ProSpec-Tany TechnoGene Ltd.) at 37°C for 16 h.

Reverse transcription-quantitative PCR (RT-qPCR)

RNA was extracted from the cultured cells using an Illustra RNAspin kit (GE Healthcare). To denature RNA, the RNA solution was heated at 70°C for 5 min and was then cooled immediately on ice. Subsequently, RT was performed at 37°C for 1 h using oligo(dT)18 primer (FASMAC), M-MLV reverse transcriptase (Thermo Fisher Scientific, Inc.) and dNTP mix (Thermo Fisher Scientific, Inc.), followed by inactivation of the enzyme at 70°C for 10 min. The cDNA for 18S, CXCL10, IFN-β, ISG56, ISG60 and MDA5 were amplified using SsoAdvanced Universal SYBR Green Supermix (Bio-Rad Laboratories, Inc.) with a qPCR system (Bio-Rad Laboratories, Inc.). The thermocycling conditions were as follows: Pre-denaturation at 95°C for 30 sec; followed by 40 cycles at 95°C for 10 sec, 60°C for 10 sec and 72°C for 20 sec; and final extension at 72°C for 5 min. 18S ribosomal RNA was utilized as an internal control. The 2−ΔΔCq method (19) was used for quantification. CXCL10 and IFN-β mRNA expression levels are presented in arbitrary units, as these genes were not detectable in the cells not stimulated with poly IC. The mRNA expression levels of the other genes are expressed as a fold increase compared with unstimulated cells. The following primers (custom composites purchased from FASMAC) were used: 18S (NR_146146.1), forward (F) 5′-ACTCAACACGGGAAACCTCA-3′, reverse (R) 5′-AACCAGACAAATCGCTCCAC-3′; CXCL10 (NM_001565.4), F 5′-TTCAAGGAGTACCTCTCTCTAG-3′, R 5′-CTGGATTCAGACATCTCTTCTC-3′; IFN-β (NM_002176.4), F 5′-CCTGTGGCAATTGAATGGGAGGC-3′, R 5′-CCAGGCACAGTGACTGTACTCCTT-3′; ISG56 (NM_001270930.2), F 5′-TAGCCAACATGTCCTCACAGAC-3′, R 5′-TCTTCTACCACTGGTTTCATGC-3′; ISG60 (NM_001031683.4), F: 5′-GAACATGCTGACCAAGCAGA-3′, R 5′-CAGTTGTGTCCACCCTTCCT-3′; MDA5 (XM_047445407.1), F 5′-GTTGAAAAGGCTGGCTGAAAAC-3′, R 5′-TCGATAACTCCTGAACCACTG-3′.

Western blotting

After cultivation, the cells were washed twice using phosphate-buffered saline, scraped from the dish and Laemmli sample buffer (Cell Signaling Technologies, Inc.) was used for protein extraction. The BCA protein assay kit (FUJIFILM Wako Pure Chemical Corporation) was used for protein quantification. Proteins (20 mg/lane) in the lysates were resolved using SDS-PAGE on 5–20% gels (ATTO Corporation) and were transferred to polyvinylidene difluoride membranes (Merck KGaA). The membranes were blocked with Tris-buffered saline containing 5% nonfat dry milk at 25°C for 2 h, and were then incubated with the following primary antibodies: Rabbit anti-ISG56 (1:3,000; cat. no. GTX118713; GeneTex, Inc.), rabbit anti-ISG60 (1:5,000; cat. no. GTX112442; GeneTex, Inc.), rabbit anti-signal transducer and activator transcription 1 (STAT1) (1:10,000; cat. no. sc-592; Santa Cruz Biotechnology, Inc.), mouse anti-phosphorylated (P)-STAT1 (1:5,000; cat. no. sc-136229; Santa Cruz Biotechnology, Inc.) and rabbit anti-actin IgG (1:5,000; cat. no. A5060; MilliporeSigma) at 4°C overnight. After washing, the membranes were incubated with horseradish peroxidase (HRP)-labeled secondary anti-mouse (1:10,000; cat. no. A28177; Thermo Fisher Scientific, Inc.) or anti-rabbit (1:10,000; cat. no. 458; Medical & Biological Laboratories Co., Ltd.) IgG at 25°C for 1 h. The Luminata Crescendo Western HRP Substrate (Merck KGaA) was utilized for detection.

Enzyme-linked immunosorbent assay (ELISA)

After incubation, the conditioned medium was recovered and centrifuged at 10,000 × g at 4°C for 10 min. IFN-β and CXCL10 protein concentrations in the collected supernatant were assessed using commercial sandwich ELISA kits from PBL Assay Science (cat. no. 41435-1) and R&D Systems, Inc. (cat. no. DIP100), respectively. The assays were performed according to the manufacturers' protocols.

Statistical analysis

The results of RT-qPCR and ELISA are shown using box plots, which are presented as the median (center of the box), 25th percentile (bottom of the box), 75th percentile (top of the box) and range (minimum and maximum), or as the mean ± standard deviation. The Mann-Whitney U-test, or one-way ANOVA and Dunnett's post hoc test were utilized for statistical analyses using EZR software version 1.65 (20) (Saitama Medical Center, Jichi Medical University, Saitama, Japan). P<0.05 was considered to indicate a statistically significant difference.

Results

Expression of ISG60 in BEAS-2B cells treated with poly IC

In unstimulated BEAS-2B cells, only small amounts of ISG60 protein and mRNA were expressed. The protein and mRNA expression levels of ISG60 increased in cells supplemented with poly IC. At ≤10 µg/ml, poly IC did not affect the protein and mRNA expression levels of ISG60, whereas ISG60 expression was markedly upregulated in response to 30–50 µg/ml poly IC (Fig. 1A and B). Therefore, the cells were supplemented with 30 µg/ml poly IC in subsequent experiments. The mRNA expression levels of ISG60 were markedly increased at 4–16 h and declined at 24 h in cells treated with poly IC (Fig. 1C). Furthermore, IFN-β mRNA was not detected in unstimulated cells. Increased expression levels of ISG60 protein were observed in cells treated with poly IC at 8 h, which progressively increased until 24 h (Fig. 1D). Transient expression of IFN-β mRNA was detected 2 h after poly IC treatment (Fig. 1E). IFN-β protein levels were transiently detected in the conditioned medium from cells treated with poly IC; they peaked at 4 h and quickly decreased thereafter (Fig. 1F).

Figure 1.

Poly IC induces the expression of ISG60 in BEAS-2B bronchial epithelial cells. (A and B) BEAS-2B cells were cultured and stimulated with different concentrations of the Toll-like receptor 3 agonist poly IC. (A) After 16 h, RNA was extracted from the cells, and RT-qPCR analysis of ISG60 mRNA was performed. Data are presented as box plots showing the median (center of the box), 25th percentile (bottom of the box), 75th percentile (top of the box) and range (minimum and maximum), and were analyzed using one-way ANOVA and Dunnett's test, n=3. *P<0.05. (B) Cellular proteins were extracted after 24 h, and western blotting was performed for ISG60 and actin. (C-F) Cells were stimulated with 30 µg/ml poly IC for up to 24 h. (C) ISG60 mRNA expression levels were detected using RT-qPCR analysis. (D) ISG60 protein expression levels in cell lysates were detected using western blotting. (E) IFN-b mRNA expression was examined using RT-qPCR analysis. (F) IFN-β protein concentration in the conditioned medium was measured using enzyme-linked immunosorbent assay. (C, E and F) Data are presented as the mean ± SD (n=3). IFN-β, interferon β; ISG60, IFN-stimulated gene 60; poly IC, polyinosinic-polycytidylic acid; RT-qPCR, reverse transcription-quantitative PCR.

IFN-β serves a role in poly IC-induced expression of ISG60 in BEAS-2B cells

As shown in Fig. 1E and F, IFN-β mRNA and protein was not detected in cells without poly IC stimulation, thus suggesting that no IFN-β mRNA and protein are expressed in unstimulated BEAS-2B cells. In the medium collected from cells transfected with control siRNA or IFN-β siRNA without poly IC-stimulation, IFN-β protein was not detected (Fig. 2A), and IFN-β mRNA expression was also not detected in those cells (Fig. 2B). Transfection of BEAS-2B cells with siRNA against IFN-β resulted in almost complete knockdown of IFN-β protein and mRNA expression in poly IC-stimulated cells, suggesting that transfection of IFN-β siRNA was successful (Fig. 2A and B). In addition, knockdown of IFN-β almost completely suppressed ISG60 mRNA (Fig. 2C) and protein (Fig. 2D) expression upon poly IC treatment. By contrast, treatment of BEAS-2B cells with 1 ng/ml r(h)IFN-β increased the expression levels of ISG60 mRNA (Fig. 2E) and protein (Fig. 2F).

Figure 2.

IFN-β is involved in poly IC-induced ISG60 expression. The cells were transfected with a specific siRNA against IFN-β and were incubated for 24 h. Then, the cells were treated with 30 µg/ml poly IC. (A) After 4 h incubation, the medium was collected and IFN-β concentration was measured using an enzyme-linked immunosorbent assay. (B) After 2 h incubation, RNA was extracted and IFN-β mRNA expression was examined using RT-qPCR. (C) After 16 h incubation, RNA was extracted, and ISG60 mRNA expression was examined. (D) ISG60 protein expression was analyzed using western blotting after 24 h. The cells were treated with r(h)IFN-β for 16 h and were subjected to (E) RT-qPCR and (F) western blotting. *P<0.05 using Mann-Whitney U-test; n=3. IFN-β, interferon β; ISG, IFN-stimulated gene; poly IC, polyinosinic-polycytidylic acid; r(h), recombinant human; RT-qPCR, reverse transcription-quantitative PCR; si, small interfering.

ISG56 is associated with ISG60 expression

The present study assessed the function of ISG56 on ISG60 expression. ISG56 mRNA and protein knockdown was confirmed using RT-qPCR (Fig. 3B) and western blotting in poly IC-treated cells, respectively (Fig. 3C). Notably, there was no significant difference between groups in unstimulated cells, because ISG56 protein expression was not detectable in unstimulated cells (Fig. 3C). ISG56 knockdown markedly reduced poly IC-induced expression of ISG60 mRNA (Fig. 3A) and slightly reduced poly IC-induced ISG60 protein (Fig. 3C). However, P-STAT1 expression was not affected by ISG56 knockdown (Fig. 3D).

Figure 3.

ISG56 is involved in poly IC-induced ISG60 expression. The cells were transfected with a specific siRNA against ISG56 and were incubated with poly IC for 16 h (for ISG60 and ISG56 mRNA analysis), 24 h (for ISG60 and ISG56 protein analysis) and 6 h (for P-STAT1 and STAT1 protein analysis). (A) ISG60 and (B) ISG56 mRNA expression was examined using reverse transcription-quantitative PCR. *P<0.05 using Mann-Whitney U-test; n=3. (C) Protein expression levels of ISG60, ISG56, and (D) P-STAT1 and STAT1 were investigated using western blotting. ISG, IFN-stimulated gene; P-, phosphorylated; poly IC, polyinosinic-polycytidylic acid; si, small interfering; STAT1, signal transducer and activator transcription 1.

ISG60 is implicated in poly IC-mediated expression of ISG56 and CXCL10, but does not affect IFN-β expression and STAT1 phosphorylation

Transfection of the cells with ISG60 si-1 and ISG60 si-2, followed by western blotting, demonstrated that these two siRNAs markedly decreased poly IC-induced ISG60 expression, suggesting that ISG60 expression was successfully knocked down (Fig. 4A). Furthermore, ISG60 knockdown decreased poly IC-induced protein and mRNA expression levels of ISG56 (Fig. 4A and D), and protein concentration and mRNA expression levels of CXCL10 (Fig. 4C and D), whereas no notable change was observed in P-STAT1 or STAT1 protein expression (Fig. 4B). Furthermore, knockdown of ISG60 using ISG60 si-1 did not affect the mRNA expression levels of IFN-β (Fig. 4D). In order to examine whether ISG60 selectively inhibits poly IC-induced expression of ISG56 and CXCL10, or inhibits the expression of all ISGs, the present study next examined the effect of ISG60 knockdown on the poly IC-induced expression of another ISG, MDA5. MDA5 was chosen because it is one of the key ISGs in antiviral innate immune reactions (21). The results revealed that poly IC-induced MDA5 mRNA expression was not affected by transfection with ISG60 si-1 (Fig. 4D). These results suggested that ISG56 and CXCL10 were selectively regulated by ISG60. Transfection of cells with ISG60 si-2 slightly decreased the mRNA expression levels of IFN-β and MDA5, and this may be due to weak non-specific effects.

Figure 4.

ISG60 is partially involved in poly IC-induced expression of CXCL10 and ISG56. The cells transfected with two different ISG60 siRNAs were treated with poly IC. (A) After incubating for 24 h, the cells were lysed and subjected to western blotting for ISG56, ISG60 and actin. (B) After incubating for 6 h, the cells were lysed and subjected to western blotting for P-STAT1, STAT1 and actin, (C) After 24 h incubation, the cell-conditioned medium was collected, and the concentration of CXCL10 protein was measured using an enzyme-linked immunosorbent assay. (D) After incubating for 2 h (for IFN-β mRNA analysis) or 16 h (for CXCL10, ISG56 and MDA5 mRNA analysis), RNA was extracted from the cells, and reverse transcription-quantitative PCR was performed. *P<0.05 using Mann-Whitney U-test; n=3. CXCL10, C-X-C motif chemokine ligand 10; IFN-β, interferon β; ISG, IFN-stimulated gene; MDA, melanoma differentiation-associated gene 5; NS, not significant; P-, phosphorylated; poly IC, polyinosinic-polycytidylic acid; si, small interfering; STAT1, signal transducer and activator transcription 1.

Discussion

Previous studies have shown that TLR3 is expressed in various cell types, including dendritic cells (22), fibroblasts (23), intestinal epithelial cells (24) and airway epithelial cells (25). TLR3 serves a physiological function in antiviral innate immunity and is involved in various inflammatory conditions (26); for example, TLR3-deficient mice have been reported to be susceptible to encephalomyocarditis virus compared with wild-type mice, whereas they were resistant to influenza virus (27). TLR3 activates the signal transduction cascade after recognizing virus-derived dsRNA to facilitate the transcription of type I IFNs. IFN-β is a type I IFN mainly expressed in bronchial epithelial cells, which induces the expression of ISGs that function in antiviral host defense reactions.

The present study confirmed that the expression of ISG60 in BEAS-2B cells was time- and concentration-dependent when stimulated by poly IC. This finding is consistent with those of previous studies showing poly IC-induced ISG60 expression in U373MG astrocytoma cells (28) and hCMEC/D3 human brain microvascular endothelial cells (29). These findings suggested that ISG60 may have a role in congenital antiviral immune responses in various tissues, including bronchial epithelial cells. Because ISG60 is a member of the ISG family, the present study investigated whether de novo-produced IFN-β contributes to poly IC-induced ISG60 expression using RNA interference against IFN-b. As a result, IFN-β knockdown largely suppressed poly IC-induced ISG60 expression, and the induction of ISG60 protein and mRNA expression was observed in BEAS-2B cells treated with r(h)IFN-β. These results indicated that poly IC-induced ISG60 expression may be dependent on newly synthesized IFN-β, and ISG60 was implicated in TLR3/IFN-β-mediated antiviral reactions in BEAS-2B cells.

CXCL10, a CXC chemokine, is a robust chemoattractant of T lymphocytes and natural killer cells, which serves various roles in the pathogenesis of inflammatory diseases and infections (30). The expression of CXCL10 must be tightly regulated to induce chemotaxis of appropriate numbers of lymphocytes to the site of infection (31). Insufficient CXCL10 expression can exacerbate viral infections, while excessive CXCL10 can lead to excessive lymphocyte infiltration, resulting in tissue injury (32). Moreover, CXCL10 protein levels in serum and the severity of acute respiratory virus infection have been shown to be correlated (33). Therefore, ‘fine-tuning’ CXCL10 expression is crucial for appropriate immune responses in the airway. In the current study, ISG60 knockdown using two different siRNAs partially decreased poly IC-induced CXCL10 mRNA expression and protein levels. These findings indicated that ISG60 may not be the primary regulator of CXCL10 expression, but may be implicated in the ‘fine-tuning’ of TLR3-mediated CXCL10 expression in BEAS-2B cells. This finding is consistent with that of a previous study in U373 astrocytoma cells (28).

Phosphorylation of STAT1 is an important step in the signaling pathway induced by IFN-β. In the present study, poly IC-induced IFN-β expression and subsequent STAT1 phosphorylation were not affected by ISG60 knockdown in BEAS-2B cells. This finding suggested that ISG60 may be involved in a reaction downstream of the IFN-β/STAT1 axis. However, this finding is in contrast to the results of a previous study in U373 cells, in which ISG60 positively regulated STAT1 phosphorylation (28). Additionally, in hCMEC/D3 brain endothelial cells, ISG60 negatively regulated TLR3-induced signaling (29). These differences indicated that ISG60 may function differently in various cell types.

ISG60, also known as IFIT3 (34), is a tetratricopeptide repeat protein that participates in various biological processes, including protein-protein and protein-RNA interactions within multi-molecule complexes. These proteins regulate chaperones, transcription, splicing, cell cycle control, protein transport, and phosphate turnover (35). In addition, ISG56/IFIT1 is known to be linked to innate immunity (11). In a previous study, we reported that ISG56 may be implicated in poly IC-induced CXCL10 expression in BEAS-2B cells (14). ISG56 is considered a partner molecule of ISG60 (11); therefore, this relationship was further assessed in the present study. ISG60 knockdown decreased poly IC-induced ISG56 expression, whereas poly IC-induced expression of MDA5, another innate immunity-related ISG, remained unchanged upon ISG60 knockdown. These findings suggested that ISG60 may selectively regulate ISG56 expression. By contrast, ISG56 knockdown decreased ISG60 expression, whereas the P-STAT1 expression did not change. These findings indicated that ISG60 and ISG56 are mutually regulated downstream of P-STAT1 in poly IC-treated BEAS-2B cells.

Because IFIT proteins, including ISG60 and ISG56, are known to have broad-spectrum antiviral functions (36), the results of the present study suggested that ISG60 and ISG56 may serve crucial roles in antiviral innate immune reactions in airway epithelial cells. Gene expression is regulated by protein complexes containing transcriptional factors, transcriptional regulators, coactivators and RNA polymerase. In addition, other components, including non-coding RNAs, are involved in the precise control of the gene expression. It has been reported that IFIT proteins regulate antiviral immune reactions by mediating a variety of protein-protein and protein-RNA interactions (11). Therefore, it was hypothesized that ISG60, as a component of a multiple protein complex, may regulate the expression of ISG56 and CXCL10 via protein-protein and/or protein-RNA interactions. However, the present study has some limitations. First, the study did not clarify the specific molecular mechanisms by which ISG60 regulates the poly IC-induced expression of CXCL10, or by which ISG60 and ISG56 regulate each other. Future studies should assess the detailed pathways and interactions involved. Second, the present study did not examine an experimental model with ISG60 upregulation. Third, this study only used an in vitro cell culture system. Future studies using lentiviral transfection to upregulate ISG60 or animal models may enhance the relevance and applicability of the present findings.

In conclusion, the present study demonstrated that ISG60 was upregulated by TLR3 signaling and may have a role in the ‘fine-tuning’ of CXCL10 expression in BEAS-2B cells. The present study reported that the TLR3/IFN-β/ISG60/CXCL10 axis (Fig. 5) may be a novel mechanism to enhance antiviral innate immune responses in bronchial epithelial cells. This axis may be important in antiviral immunity in the respiratory tract and appropriate activation of this axis could contribute to the host defense against viral infection. However, excess or dysregulated activation of this axis may lead to excess accumulation of lymphocytes; since excess accumulation of lymphocytes induces the excess activation of cytokine networks (37), dysregulated activation of this axis may exacerbate inflammation and airway injury induced by viral infection. Therefore, this axis may be involved in both physiological antiviral innate immune reaction and pathological inflammation induced by viral infection in the airways. The present findings suggested that ISG60 may serve as a potential target for developing new therapeutic strategies against viral respiratory infections.

Figure 5.

Schematic model of ISG60 expression downstream of TLR3 signaling in bronchial epithelial cells. CXCL10, C-X-C motif chemokine ligand 10; dsRNA, double-stranded RNA; IFN, interferon; ISG, IFN-stimulated gene; P-STAT1, phosphorylated-signal transducer and activator transcription 1; si, small interfering; TLR3, Toll-like receptor 3.

Acknowledgements

The authors would like to thank Ms. Michiko Nakata (Department of Neuropathology, Hirosaki University Graduate School of Medicine) for technical support.

Funding

Funding: No funding was received.

Availability of data and materials

The data generated in the present study may be requested from the corresponding author.

Authors' contributions

YT and TI contributed to all experiments and prepared the manuscript. YK performed the ELISA. MT performed the western blotting. TS, MD and MS performed the RNA extraction and RT-qPCR analyses. SK and KS performed the cell culturing. TI and ST designed the study. All authors have read and approved the final version of the manuscript. YT and TI confirm the authenticity of all the raw data.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Glossary

Abbreviations

Abbreviations:

CXCL10

C-X-C motif chemokine ligand 10

dsRNA

double-stranded RNA

ELISA

enzyme-linked immunosorbent assay

IFN

interferon

IFIT1

IFN-induced protein with tetratricopeptide repeats 1

ISG

IFN-stimulated gene

MDA5

melanoma differentiation-associated gene 5

P-STAT1

phosphorylated-signal transducer and activating transcription-1

poly IC

polyinosinic-polycytidylic acid

RT-qPCR

reverse transcription-quantitative PCR

r(h)IFN-β

recombinant human IFN-β

siRNA

small interfering RNA

TLR3

Toll-like receptor 3

References

1 

Bakaletz LO: Viral-bacterial co-infections in the respiratory tract. Curr Opin Microbiol. 35:30–35. 2017. View Article : Google Scholar : PubMed/NCBI

2 

Medzhitov R and Janeway C Jr: Innate immunity: Impact on the adaptive immune response. Curr Opin Immunol. 9:4–9. 1997. View Article : Google Scholar : PubMed/NCBI

3 

Okahira S, Nishikawa F, Nishikawa S, Akazawa T, Seya T and Matsumoto M: Interferon-beta induction through toll-like receptor 3 depends on double-stranded RNA structure. DNA Cell Biol. 24:614–623. 2005. View Article : Google Scholar : PubMed/NCBI

4 

Guillot L, Le Goffic R, Bloch S, Escriou N, Akira S, Chignard M and Si-Tahar M: Involvement of toll-like receptor 3 in the immune response of lung epithelial cells to double-stranded RNA and influenza A virus. J Biol Chem. 280:5571–5580. 2005. View Article : Google Scholar : PubMed/NCBI

5 

Yu M and Levine SJ: Toll-like receptor, RIG-I-like receptors and the NLRP3 inflammasome: Key modulators of innate immune responses to double-stranded RNA viruses. Cytokine Growth Factor Rev. 22:63–72. 2011. View Article : Google Scholar : PubMed/NCBI

6 

Kawai T and Akira S: The role of pattern-recognition receptors in innate immunity: Update on Toll-like receptors. Nat Immunol. 11:373–384. 2010. View Article : Google Scholar : PubMed/NCBI

7 

Hsu ACY, Parsons K, Barr I, Lowther S, Middleton D, Hansbro PM and Wark PAB: Critical role of constitutive type I interferon response in bronchial epithelial cell to influenza infection. PLoS One. 7:e329472012. View Article : Google Scholar : PubMed/NCBI

8 

Majde JA: Viral double-stranded RNA, cytokines, and the flu. J Interferon Cytokine Res. 20:259–272. 2000. View Article : Google Scholar : PubMed/NCBI

9 

Hamamdzic D, Phillips-Dorsett T, Altman-Hamamdzic S, London SD and London L: Reovirus triggers cell type-specific proinflammatory responses dependent on the autocrine action of IFN-beta. Am J Physiol Lung Cell Mol Physiol. 280:L18–L29. 2001. View Article : Google Scholar : PubMed/NCBI

10 

Imaizumi T, Aizawa-Yashiro T, Tsuruga K, Tanaka H, Matsumiya T, Yoshida H, Tatsuta T, Xing F, Hayakari R and Satoh K: Melanoma differentiation-associated gene 5 regulates the expression of a chemokine CXCL10 in human mesangial cells: Implications for chronic inflammatory renal diseases. Tohoku J Exp Med. 228:17–61. 2012. View Article : Google Scholar : PubMed/NCBI

11 

Fensterl V and Sen GC: The ISG56/IFIT1 gene family. J Interferon Cytokine Res. 31:71–78. 2011. View Article : Google Scholar : PubMed/NCBI

12 

Vareille M, Kieninger E, Edwards MR and Regamey N: The airway epithelium: Soldier in the fight against respiratory viruses. Clin Microbiol Rev. 24:210–219. 2011. View Article : Google Scholar : PubMed/NCBI

13 

Sanders CJ, Doherty PC and Thomas PG: Respiratory epithelial cells in innate immunity to influenza virus infection. Cell Tissue Res. 343:13–21. 2011. View Article : Google Scholar : PubMed/NCBI

14 

Shiratori T, Imaizumi T, Hirono K, Kawaguchi S, Matsumiya T, Seya K and Tasaka S: ISG56 is involved in CXCL10 expression induced by TLR3 signaling in BEAS-2B bronchial epithelial cells. Exp Lung Res. 46:195–202. 2020. View Article : Google Scholar : PubMed/NCBI

15 

Yu M, Tong JH, Mao M, Kan LX, Liu MM, Sun YW, Fu G, Jing YK, Yu L, Lepaslier D, et al: Cloning of a gene (RIG-G) associated with retinoic acid-induced differentiation of acute promyelocytic leukemia cells and representing a new member of a family of interferon-stimulated genes. Proc Natl Acad Sci USA. 94:7406–7411. 1997. View Article : Google Scholar : PubMed/NCBI

16 

Zhou X, Michal JJ, Zhang L, Ding B, Lunney JK, Liu B and Jiang Z: Interferon induced IFIT family genes in host antiviral defense. Int J Biol Sci. 9:200–208. 2013. View Article : Google Scholar : PubMed/NCBI

17 

Chikhalya A, Dittmann M, Zheng Y, Sohn SC, Rice CM and Hearing P: Human IFIT3 protein induced interferon signaling and inhibits adenovirus immediate early gene expression. mBio. 12:e02829212021. View Article : Google Scholar : PubMed/NCBI

18 

Imaizumi T, Tanaka H, Matsumiya T, Yoshida H, Tanji K, Tsuruga K, Oki E, Aizawa-Yashiro T, Ito E and Satoh K: Retinoic acid-inducible gene-I is induced by double-stranded RNA and regulates the expression of CC chemokine ligand (CCL) 5 in human mesangial cells. Nephrol Dial Transplant. 25:3534–3539. 2010. View Article : Google Scholar : PubMed/NCBI

19 

Schmittgen TD and Livak KJ: Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc. 3:1101–1108. 2008. View Article : Google Scholar : PubMed/NCBI

20 

Kanda Y: Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 48:452–458. 2013. View Article : Google Scholar : PubMed/NCBI

21 

Schoggins JW, Wilson SJ, Panis M, Murphy MY, Jones CT, Bieniasz P and Rice CM: A diverse range of gene products are effectors of the type I interferon antiviral response. Nature. 472:481–485. 2011. View Article : Google Scholar : PubMed/NCBI

22 

Muzio M, Bosisio D, Polentarutti N, D'amico G, Stoppacciaro A, Mancinelli R, van't Veer C, Penton-Rol G, Ruco LP, Allavena P and Mantovani A: Differential expression and regulation of toll-like receptors (TLR) in human leukocytes: Selective expression of TLR3 in dendritic cells. J Immunol. 164:5998–6004. 2000. View Article : Google Scholar : PubMed/NCBI

23 

Matsumoto M, Kikkawa S, Kohase M, Miyake K and Seya T: Establishment of a monoclonal antibody against human Toll-like receptor 3 that blocks double-stranded RNA-mediated signaling. Biochem Biophys Res Commun. 293:1364–1369. 2002. View Article : Google Scholar : PubMed/NCBI

24 

Cario E and Podolsky DK: Differential alteration in intestinal epithelial cell expression of toll-like receptor 3 (TLR3) and TLR4 in inflammatory bowel disease. Infect Immun. 68:7010–7017. 2000. View Article : Google Scholar : PubMed/NCBI

25 

Lai Y, Yi G, Chen A, Bhardwaj K, Tragesser BJ, Valverde RA, Zlotnick A, Mukhopadhyay S, Ranjith-Kumar CT and Kao CC: Viral double-strand RNA-binding proteins can enhance innate immune signaling by toll-like Receptor 3. PLoS One. 6:e258372011. View Article : Google Scholar : PubMed/NCBI

26 

Matsumoto M and Seya T: TLR3: Interferon induction by double-stranded RNA including poly(I:C). Adv Drug Deliv Rev. 60:805–812. 2008. View Article : Google Scholar : PubMed/NCBI

27 

Zhang SY, Herman M, Ciancanelli MJ, Pérez de Diego R, Sancho-Shimizu V, Abel L and Casanova JL: TLR3 immunity to infection inmice and humans. Curr Opin Immunol. 25:19–33. 2013. View Article : Google Scholar : PubMed/NCBI

28 

Imaizumi T, Yoshida H, Hayakari R, Xing F, Wang L, Matsumiya T, Tanji K, Kawaguchi S, Murakami M and Tanaka H: Interferon-stimulated gene (ISG) 60, as well as ISG56 and ISG54, positively regulates TLR3/IFN-β/STAT1 axis in U373MG human astrocytoma cells. Neurosci Res. 105:35–41. 2016. View Article : Google Scholar : PubMed/NCBI

29 

Imaizumi T, Sassa N, Kawaguchi S, Matsumiya T, Yoshida H, Seya K, Shiratori T, Hirono K and Tanaka H: Interferon-stimulated gene 60 (ISG60) constitutes a negative feedback loop in the downstream of TLR3 signaling in hCMEC/D3 cells. J Neuroimmunol. 324:16–21. 2018. View Article : Google Scholar : PubMed/NCBI

30 

Liu M, Guo S, Hibbert JM, Jain V, Singh N, Wilson NO and Stiles JK: CXCL10/IP-10 in infectious diseases pathogenesis and potential therapeutic implications. Cytokine Growth Factor Rev. 22:121–130. 2011.PubMed/NCBI

31 

Dwinell MB, Lugering N, Eckmann L and Kangnoff MF: Regulated production of interferon-inducible T-cell chemoattractants by human intestinal epithelial cells. Gastroenterology. 120:49–59. 2001. View Article : Google Scholar : PubMed/NCBI

32 

Frangogiannis NG, Mendoza LH, Smith CW, Michael LH and Entman ML: Induction of the synthesis of the C-X-C chemokine interferon-gamma-inducible protein-10 in experimental canine endotoxemia. Cell Tissue Res. 302:365–376. 2000. View Article : Google Scholar : PubMed/NCBI

33 

Hayney MS, Henriquez KM, Barnet JH, Ewers T, Champion HM, Flannery S and Barrett B: Serum IFN-γ-induced protein 10 (IP-10) as a biomarker for severity of acute respiratory infection in healthy adults. J Clin Virol. 90:32–37. 2017. View Article : Google Scholar : PubMed/NCBI

34 

Schmeisser H, Mejido J, Balinsky CA, Morrow AN, Clark CR, Zhao T and Zoon KC: Identification of alpha interferon-induced genes associated with antiviral activity in Daudi cells and characterization of IFIT3 as a novel antiviral gene. J Virol. 84:10671–10680. 2010. View Article : Google Scholar : PubMed/NCBI

35 

Blatch GL and Lässle M: The tetratricopeptide repeat: A structural motif mediating protein-protein interactions. Bioessays. 21:932–939. 1999. View Article : Google Scholar : PubMed/NCBI

36 

Diamond MS and Farzan M: The broad-spectrum antiviral functions of IFIT and IFITM proteins. Nat Rev Immunol. 13:46–57. 2013. View Article : Google Scholar : PubMed/NCBI

37 

Tang Y, Liu J, Zhang D, Xu Z, Ji J and Wen C: Cytokine storm in COVID-19: The current evidence and treatment strategies. Front Immunol. 11:17082020. View Article : Google Scholar : PubMed/NCBI

Related Articles

  • Abstract
  • View
  • Download
  • Twitter
Copy and paste a formatted citation
Spandidos Publications style
Tanaka Y, Imaizumi T, Kobori Y, Tachizaki M, Shiratori T, Dobashi M, Sato M, Kawaguchi S, Seya K, Tasaka S, Tasaka S, et al: Expression of ISG60 is induced by TLR3 signaling in BEAS‑2B bronchial epithelial cells: Possible involvement in CXCL10 expression. Mol Med Rep 30: 151, 2024.
APA
Tanaka, Y., Imaizumi, T., Kobori, Y., Tachizaki, M., Shiratori, T., Dobashi, M. ... Tasaka, S. (2024). Expression of ISG60 is induced by TLR3 signaling in BEAS‑2B bronchial epithelial cells: Possible involvement in CXCL10 expression. Molecular Medicine Reports, 30, 151. https://doi.org/10.3892/mmr.2024.13276
MLA
Tanaka, Y., Imaizumi, T., Kobori, Y., Tachizaki, M., Shiratori, T., Dobashi, M., Sato, M., Kawaguchi, S., Seya, K., Tasaka, S."Expression of ISG60 is induced by TLR3 signaling in BEAS‑2B bronchial epithelial cells: Possible involvement in CXCL10 expression". Molecular Medicine Reports 30.3 (2024): 151.
Chicago
Tanaka, Y., Imaizumi, T., Kobori, Y., Tachizaki, M., Shiratori, T., Dobashi, M., Sato, M., Kawaguchi, S., Seya, K., Tasaka, S."Expression of ISG60 is induced by TLR3 signaling in BEAS‑2B bronchial epithelial cells: Possible involvement in CXCL10 expression". Molecular Medicine Reports 30, no. 3 (2024): 151. https://doi.org/10.3892/mmr.2024.13276
Copy and paste a formatted citation
x
Spandidos Publications style
Tanaka Y, Imaizumi T, Kobori Y, Tachizaki M, Shiratori T, Dobashi M, Sato M, Kawaguchi S, Seya K, Tasaka S, Tasaka S, et al: Expression of ISG60 is induced by TLR3 signaling in BEAS‑2B bronchial epithelial cells: Possible involvement in CXCL10 expression. Mol Med Rep 30: 151, 2024.
APA
Tanaka, Y., Imaizumi, T., Kobori, Y., Tachizaki, M., Shiratori, T., Dobashi, M. ... Tasaka, S. (2024). Expression of ISG60 is induced by TLR3 signaling in BEAS‑2B bronchial epithelial cells: Possible involvement in CXCL10 expression. Molecular Medicine Reports, 30, 151. https://doi.org/10.3892/mmr.2024.13276
MLA
Tanaka, Y., Imaizumi, T., Kobori, Y., Tachizaki, M., Shiratori, T., Dobashi, M., Sato, M., Kawaguchi, S., Seya, K., Tasaka, S."Expression of ISG60 is induced by TLR3 signaling in BEAS‑2B bronchial epithelial cells: Possible involvement in CXCL10 expression". Molecular Medicine Reports 30.3 (2024): 151.
Chicago
Tanaka, Y., Imaizumi, T., Kobori, Y., Tachizaki, M., Shiratori, T., Dobashi, M., Sato, M., Kawaguchi, S., Seya, K., Tasaka, S."Expression of ISG60 is induced by TLR3 signaling in BEAS‑2B bronchial epithelial cells: Possible involvement in CXCL10 expression". Molecular Medicine Reports 30, no. 3 (2024): 151. https://doi.org/10.3892/mmr.2024.13276
Follow us
  • Twitter
  • LinkedIn
  • Facebook
About
  • Spandidos Publications
  • Careers
  • Cookie Policy
  • Privacy Policy
How can we help?
  • Help
  • Live Chat
  • Contact
  • Email to our Support Team